What is ambutra? Decoding the Medication Amvuttra (Vutrisiran)
•
3 min read
In 2022, the FDA approved Amvuttra (vutrisiran) as a major therapeutic advance for specific types of amyloidosis. Often mistakenly searched for as 'ambutra,' this medication represents a powerful form of gene-silencing therapy that targets the root cause of hereditary transthyretin-mediated (hATTR) amyloidosis.
